Impact of Whey and Leucine on Glycaemia in Adults Without Diabetes

NCT ID: NCT03785951

Last Updated: 2018-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Higher than average blood sugar (glucose) levels are linked to an increased risk of developing type 2 diabetes. As such, there is interest in identifying dietary factors that could lower blood glucose to help reduce the number of people with this disease. Findings from some human studies indicate that dairy products, especially a milk protein (whey), may help the control of blood glucose levels. However, there is a need for further studies to confirm these findings in individuals without diabetes but with higher than average blood glucose levels.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the UK, more than 700 people are diagnosed with type 2 diabetes each day. Higher than average (raised) fasting blood sugar (glucose) is a characteristic of those at risk of developing this disease and as a result there is significant interest in dietary factors that could reduce levels of blood glucose, lowering the frequency of type 2 diabetes in the population. Existing scientific evidence suggests an important role of dairy products and especially of whey protein in the control of blood glucose levels. However, there is a need for further studies to confirm these findings in individuals without diabetes but with higher than average blood glucose levels.

Milk contains high quality proteins, of which 80% are caseins and 20% are whey proteins. Whey proteins are a rich source of branched-chain amino acids (such as leucine) which are thought to play an important role in regulating blood glucose control and other aspects of cardiovascular disease development in both healthy and type 2 diabetic subjects. However, very few studies in non-diabetic subjects with moderately raised HbA1c, characteristic of long-term poor glucose control, have been performed to investigate how whey protein affects blood glucose levels in the body especially when consumed over the longer term in the daily diet. Furthermore, data are limited on whether the leucine content of protein plays an important role in controlling blood glucose levels.

Study aims The main aims of this study is to investigate in adults without diabetes but with moderately raised HbA1c (a long- term marker of blood glucose control) whether a protein obtained from milk and dairy products (whey) has a beneficial effect on fasting and day-long blood glucose and insulin levels compared with a plant based protein (such as wheat). The researchers will also determine if leucine, a particular amino acid (building blocks of protein) found in higher levels in whey protein plays an important role in controlling blood glucose levels.

A secondary aim will determine whether the protein interventions influence risk markers for developing heart disease and diabetes including the level of blood lipids, hormones regulating blood sugar levels and blood vessel health.

This study will test the hypothesis that the incorporation of whey protein (total protein dose 50 g/d) in the habitual diet for 8 weeks will result in an improvement in fasting and day-long blood glucose and insulin levels, and other risk markers of heart disease and diabetes compared with wheat protein (total protein dose 50 g/d), and that the addition of leucine to wheat (to match the content found in whey protein) will improve blood glucose control.

Study design This study will be a long term, double-blind, randomised, controlled, three-way, cross-over study, in which the participants will receive the protein supplements (in random order) for 8 weeks each, with a 4 week wash-out period between the different protein treatments. At the beginning and end of each protein intervention, a fasting blood sample will be collected to determine the longer term effects of the assigned protein supplement on fasting glycaemic control, insulin sensitivity, endothelial function and other cardio-metabolic risk markers, as well as non-invasive measures of blood vessel health. At the beginning of each intervention period, a subset of participants will also undergo a day-long test meal investigation to determine the short-term (postprandial) effects of the protein interventions on the study outcome measures in response to standard sequential test meals containing the assigned protein interventions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre Diabetes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

HbA1c whey postprandial glycaemia cardiometabolic vascular leucine branched chain amino acids (BCAA) glucose control Milk protein

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Double-blind, randomised, controlled, 3-way, cross-over study
Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Coded protein products will be used.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Whey Protein Isolate

Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks

Group Type EXPERIMENTAL

Whey Protein Isolate

Intervention Type DIETARY_SUPPLEMENT

Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.

50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

Wheat Protein

Intervention Type DIETARY_SUPPLEMENT

Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.

50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

Wheat Protein with Leucine

Intervention Type DIETARY_SUPPLEMENT

Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.

50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks.

Wheat Protein

Subjects are asked to supplement their habitual diet with 56 g of wheat protein a day for 8 weeks

Group Type EXPERIMENTAL

Whey Protein Isolate

Intervention Type DIETARY_SUPPLEMENT

Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.

50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

Wheat Protein

Intervention Type DIETARY_SUPPLEMENT

Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.

50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

Wheat Protein with Leucine

Intervention Type DIETARY_SUPPLEMENT

Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.

50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks.

Wheat protein with leucine

Subjects are asked to supplement their habitual diet with 56 g of wheat protein with leucine a day for 8 weeks

Group Type EXPERIMENTAL

Whey Protein Isolate

Intervention Type DIETARY_SUPPLEMENT

Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.

50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

Wheat Protein

Intervention Type DIETARY_SUPPLEMENT

Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.

50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

Wheat Protein with Leucine

Intervention Type DIETARY_SUPPLEMENT

Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.

50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Whey Protein Isolate

Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.

50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

Intervention Type DIETARY_SUPPLEMENT

Wheat Protein

Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.

50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.

Intervention Type DIETARY_SUPPLEMENT

Wheat Protein with Leucine

Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.

50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI 20-35 kg/m2
* HbA1c (5.7 - 6.5%) or (38.8 - 47.5 mmol/mol)
* Fasting glucose 5.5-6.9 mmol/l
* Fasting total cholesterol \<7.5mmol/l
* Fasting triacylglycerol \<4.0 mmol/l
* Not having a milk, gluten or wheat allergy or lactose intolerability
* Not having diabetes (HbA1c \< 47 mmol/mol) or \< 6.5%
* Not suffering from cardiovascular, renal, gastrointestinal, respiratory, endocrine or liver disease
* Not having hypertension
* Not diagnosed with cancer
* Not having surgery in the previous 6 months
* Not consuming more than the recommended intake of alcohol (\>14 unit/wk)
* Not being a blood donor 3 months prior to or during the study.
* Not taking extra protein powder supplements in the previous 2 months
* Not anaemic (Haemoglobin ≥115 g/l for women and ≥ 130 g/l for men)
* Not taking medication for raised blood lipids, high blood pressure or for inflammatory conditions.

Exclusion Criteria

• Females who are breast-feeding, may be pregnant, or if of child-bearing potential and are not using effective contraceptive precautions
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Barnham Benevolent Foundation

UNKNOWN

Sponsor Role collaborator

Jason and Daphne Mermikides Charitable Trust

UNKNOWN

Sponsor Role collaborator

University of Reading

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Julie Lovegrove

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Julie Lovegrove, Professor

Role: PRINCIPAL_INVESTIGATOR

University of Reading

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading

Reading, Berkshire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Julie Lovegrove, Professor

Role: CONTACT

Phone: 0044(0)1183786418

Email: [email protected]

Drew Price, Masters

Role: CONTACT

Phone: 00447905106167

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Julie Lovegrove, Professor

Role: primary

Drew Price, Masters

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Pal S, Ellis V, Dhaliwal S. Effects of whey protein isolate on body composition, lipids, insulin and glucose in overweight and obese individuals. Br J Nutr. 2010 Sep;104(5):716-23. doi: 10.1017/S0007114510000991. Epub 2010 Apr 9.

Reference Type BACKGROUND
PMID: 20377924 (View on PubMed)

Nilsson M, Stenberg M, Frid AH, Holst JJ, Bjorck IM. Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr. 2004 Nov;80(5):1246-53. doi: 10.1093/ajcn/80.5.1246.

Reference Type BACKGROUND
PMID: 15531672 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17/56

Identifier Type: -

Identifier Source: org_study_id